The first quarter of 2022 delivered six reported Women's Health transaction, marking a sharp increase in transaction activity compared to the end of last year.
The first quarter of 2022 delivered three reported urology practice acquisitions, continuing a pattern of smaller deal volume and larger deal size when compared to other practice specialties undergoing
M&A consolidation.
The first quarter of 2022 delivered eleven reported ophthalmology practice acquisitions, marking a sharp decline from the flurry of closings at the end of last year This was expected as business development teams had exhausted all resources toward closing deals last quarter We will highlight a few notable deals.
The first quarter of 2022 delivered twenty-eight reported home health and hospice acquisitions, coming down from peaks levels to end the past year However, Q1 has historically brought lower M&A levels, and we expect deal volume to rebound throughout the year.
The first quarter of 2022 delivered ten reported gastroenterology practice acquisitions, continuing the high level of M&A activity we saw last year Several deals were announced in the first few weeks of the
year, likely spilling over from efforts to close in 2021.
The 4th quarter of 2021 delivered two reported cardiology platform acquisitions, signaling an imminent wave of increasing private equity investments into the specialty.
The first quarter of 2022 delivered thirty-five reported behavioral health acquisitions, returning to average deal volume after a spike in activity to end 2021. Mental health and addiction treatment continue to be at the forefront of consolidation. We will highlight a few notable deals from the period.
The 1st quarter of 2022 delivered two reported cardiology partnerships for this specialty in the Early Pioneering lifecycle stage PE interest remains consistent and seems to be building
